Literature DB >> 20660820

HK-2 human renal proximal tubule cells as a model for G protein-coupled receptor kinase type 4-mediated dopamine 1 receptor uncoupling.

John J Gildea1, Ishan Shah, Ryan Weiss, Nicholas D Casscells, Helen E McGrath, Jin Zhang, John E Jones, Robin A Felder.   

Abstract

HK-2 human renal proximal tubule cells (RPTC) are commonly used in the in vitro study of "normal" RPTCs. We discovered recently that HK-2 cells are uncoupled from dopamine 1 receptor (D(1)R) adenylyl cyclase (AC) stimulation. We hypothesized that G protein-coupled receptor kinase type 4 (GRK4) single nucleotide polymorphisms may be responsible for the D(1)R/AC uncoupling in HK-2. This hypothesis was tested by genotyping GRK4 single nucleotide polymorphisms, measuring D(1)-like receptor agonist (fenoldopam)-stimulated cAMP accumulation, quantifying D(1)R inhibition of sodium transport, and testing the ability of GRK4 small interfering RNA to reverse the D(1)R/AC uncoupling. We compared HK-2 with 2 normally coupled human RPTC cell lines and 2 uncoupled RPTC cell lines. The HK-2 cell line was found to have 4 of 6 potential GRK4 single nucleotide polymorphisms known to uncouple the D(1)R from AC (namely, R65L, A142V, and A486V). AC response to fenoldopam stimulation was increased in the 2 normally coupled human RPTC cell lines (FEN: 2.02+/-0.05-fold and 2.33+/-0.19-fold over control; P<0.001; n=4) but not in the 2 uncoupled or HK-2 cell lines. GRK4 small interfering RNA rescued the fenoldopam-mediated AC stimulation in the uncoupled cells, including HK-2. The expected fenoldopam-mediated inhibition of sodium hydrogen exchanger type 3 was absent in HK-2 (n=6) and uncoupled RPTC cell lines (n=6) but was observed in the 2 normally coupled human RPTC cell lines (-25.41+/-4.7% and -27.36+/-2.70%; P<0.001; n=6), which express wild-type GRK4. Despite the fact that HK-2 cells retain many functional characteristics of RPTCs, they are not normal from the perspective of dopaminergic function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660820      PMCID: PMC3537327          DOI: 10.1161/HYPERTENSIONAHA.110.152256

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  48 in total

1.  Amelioration of genetic hypertension by suppression of renal G protein-coupled receptor kinase type 4 expression.

Authors:  Hironobu Sanada; Junichi Yatabe; Sanae Midorikawa; Tetsuo Katoh; Shigeatsu Hashimoto; Tsuyoshi Watanabe; Jing Xu; Yingjin Luo; Xiaoyan Wang; Chunyu Zeng; Ines Armando; Robin A Felder; Pedro A Jose
Journal:  Hypertension       Date:  2006-04-24       Impact factor: 10.190

2.  Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese.

Authors:  Dongfeng Gu; Shaoyong Su; Dongliang Ge; Shufeng Chen; Jianfeng Huang; Biao Li; Runsheng Chen; Boqin Qiang
Journal:  Hypertension       Date:  2006-04-24       Impact factor: 10.190

3.  Differentiation status of human renal proximal and distal tubular epithelial cells in vitro: Differential expression of characteristic markers.

Authors:  Patrick C Baer; Jurgen Bereiter-Hahn; Ralf Schubert; Helmut Geiger
Journal:  Cells Tissues Organs       Date:  2006       Impact factor: 2.481

4.  Differential D1 and D5 receptor regulation and degradation of the angiotensin type 1 receptor.

Authors:  John J Gildea; Xiaoli Wang; Pedro A Jose; Robin A Felder
Journal:  Hypertension       Date:  2008-01-02       Impact factor: 10.190

5.  Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity.

Authors:  Robin A Felder; Pedro A Jose
Journal:  Nat Clin Pract Nephrol       Date:  2006-11

6.  Pharmacodynamic characteristics and cardioprotective effects of new NHE1 inhibitors.

Authors:  Juno Kim; Yi-Sook Jung; Wonsun Han; Mi-Young Kim; Wan Namkung; Byung Ho Lee; Kyu Yang Yi; Sung-eun Yoo; Min Goo Lee; Kyung Hwan Kim
Journal:  Eur J Pharmacol       Date:  2007-04-14       Impact factor: 4.432

7.  Plasticity of epithelial cells derived from human normal and ADPKD kidneys in primary cultures.

Authors:  Gerard Elberg; Suresh Guruswamy; Charlotte J Logan; Lijuan Chen; Martin A Turman
Journal:  Cell Tissue Res       Date:  2007-11-15       Impact factor: 5.249

8.  Lipid rafts keep NADPH oxidase in the inactive state in human renal proximal tubule cells.

Authors:  Weixing Han; Hewang Li; Van Anthony M Villar; Annabelle M Pascua; Mustafa I Dajani; Xiaoyang Wang; Aruna Natarajan; Mark T Quinn; Robin A Felder; Pedro A Jose; Peiying Yu
Journal:  Hypertension       Date:  2008-01-14       Impact factor: 10.190

9.  beta2-adrenergic receptor signaling and desensitization elucidated by quantitative modeling of real time cAMP dynamics.

Authors:  Jonathan D Violin; Lisa M DiPilato; Necmettin Yildirim; Timothy C Elston; Jin Zhang; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2007-11-28       Impact factor: 5.157

10.  Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma.

Authors:  L Campbell; M Gumbleton; D F R Griffiths
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

View more
  18 in total

Review 1.  Dopamine, the kidney, and hypertension.

Authors:  Raymond C Harris; Ming-Zhi Zhang
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

Review 2.  Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions.

Authors:  J A Johnson; S B Liggett
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

Review 3.  Genetics of salt-sensitive hypertension.

Authors:  Hironobu Sanada; John E Jones; Pedro A Jose
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

4.  The Dopamine D1 Receptor and Angiotensin II Type-2 Receptor are Required for Inhibition of Sodium Transport Through a Protein Phosphatase 2A Pathway.

Authors:  John J Gildea; Peng Xu; Brandon A Kemp; Robert M Carey; Pedro A Jose; Robin A Felder
Journal:  Hypertension       Date:  2019-06       Impact factor: 10.190

Review 5.  Abnormalities in renal dopamine signaling and hypertension: the role of GRK4.

Authors:  Raymond C Harris
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

6.  Dopamine and angiotensin type 2 receptors cooperatively inhibit sodium transport in human renal proximal tubule cells.

Authors:  John J Gildea; Xiaoli Wang; Neema Shah; Hanh Tran; Michael Spinosa; Robert Van Sciver; Midori Sasaki; Junichi Yatabe; Robert M Carey; Pedro A Jose; Robin A Felder
Journal:  Hypertension       Date:  2012-06-18       Impact factor: 10.190

7.  A linear relationship between the ex-vivo sodium mediated expression of two sodium regulatory pathways as a surrogate marker of salt sensitivity of blood pressure in exfoliated human renal proximal tubule cells: the virtual renal biopsy.

Authors:  John J Gildea; Dylan T Lahiff; Robert E Van Sciver; Ryan S Weiss; Neema Shah; Helen E McGrath; Cynthia D Schoeffel; Pedro A Jose; Robert M Carey; Robin A Felder
Journal:  Clin Chim Acta       Date:  2013-02-27       Impact factor: 3.786

8.  A novel role for c-Myc in G protein-coupled receptor kinase 4 (GRK4) transcriptional regulation in human kidney proximal tubule cells.

Authors:  John J Gildea; Hanh T Tran; Robert E Van Sciver; Dora Bigler Wang; Julia M Carlson; Robin A Felder
Journal:  Hypertension       Date:  2013-03-18       Impact factor: 10.190

9.  Human kidney-2 cells harbor functional dopamine D1 receptors that require Giα for Gq/11α signaling.

Authors:  Indira D Pokkunuri; Gaurav Chugh; Mohammad Asghar
Journal:  Am J Physiol Renal Physiol       Date:  2013-05-22

10.  Exosomal transfer from human renal proximal tubule cells to distal tubule and collecting duct cells.

Authors:  John J Gildea; Joscelyn E Seaton; Ken G Victor; Camellia M Reyes; Dora Bigler Wang; Abigail C Pettigrew; Crystal E Courtner; Neema Shah; Hanh T Tran; Robert E Van Sciver; Julia M Carlson; Robin A Felder
Journal:  Clin Biochem       Date:  2014-06-27       Impact factor: 3.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.